Analytical Data
-
Gene name
CD82
- Application
-
Alternative Names
C33 antigenIA4Inducible membrane protein R2Metastasis suppressor Kangai-1 homolog; CD82
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P40237
-
Expression Region
111-227aa
-
Molecular Weight
29.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD82, also known as lymphocyte function-associated antigen 3 (LFA-3), is a member of the tetraspanin family, which plays a critical role in various biological processes, including cell adhesion, proliferation, and immune response regulation. CD82 is particularly notable for its involvement in modulating the immune system, as it is expressed on various immune cells, including T cells, B cells, and dendritic cells. Research into CD82 has shown its potential role in cancer biology, where it can influence tumor metastasis and progression through its interactions with integrins and other cell surface molecules. Studies indicate that CD82 may function as a tumor suppressor in certain cancer types, as its expression has been associated with reduced metastatic potential and improved patient prognosis. Moreover, the re-expression of CD82 in cancer cells has been linked to enhanced immune response against tumors, suggesting that CD82 could be a valuable target for immunotherapy. Given its important biological functions and potential clinical implications, the production and characterization of recombinant CD82 protein are necessary for further investigations. Recombinant CD82 proteins can be used to study its structural characteristics, ligand interactions, and downstream signaling pathways. Additionally, these proteins may facilitate the development of novel therapeutic strategies by providing insights into CD82's role in immune modulation and cancer progression. Understanding the functioning of recombinant CD82 at the molecular level could pave the way for innovative approaches in treating cancers and improving immunotherapeutic outcomes.
